Joshua Reineke
Overview
Explore the profile of Joshua Reineke including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
453
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Irabin A, Ollewagen T, Smith C, Ahmed R, Reineke J, Reijnders R, et al.
Eur J Pharm Sci
. 2025 Feb;
207:107037.
PMID: 39933629
Since the antibiotic golden era of the mid-20th century, there have been limited antibiotics approved, while antibiotic resistance continues to escalate disproportionately, outpacing the rate of novel antibiotic discovery. This...
2.
Bahl R, Venegas Mata C, Neth B, Meinzinger L, Deppe A, Jahnke H, et al.
J Vis Exp
. 2024 Oct;
(211).
PMID: 39400162
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers with a 5-year survival rate of <12%. The biggest barrier to therapy is the dense desmoplastic extracellular matrix (ECM) that...
3.
Alseud K, Ostlund T, Durymanov M, Reineke J, Halaweish F
Bioorg Med Chem
. 2024 Mar;
103:117678.
PMID: 38489997
Pancreatic Ductal Adenocarcinoma (PDAC), representing over 90 % of pancreatic cancer diagnoses, is an aggressive disease with survivability among the worst of all cancers due to its difficulty in detection...
4.
Durymanov M, Permyakova A, Reineke J
Front Bioeng Biotechnol
. 2020 Jul;
8:495.
PMID: 32671024
Drug-induced hepatotoxicity is one of the major barriers limiting application of current pharmaceuticals as well as clinical translation of novel and perspective drugs. In this context, numerous hepatoprotective molecules have...
5.
Joseph M, Islam M, Reineke J, Hildreth M, Woyengo T, Pillatzki A, et al.
Mol Pharm
. 2019 Dec;
17(2):441-452.
PMID: 31886676
Drug delivery by direct intraductal administration can achieve high local drug concentration in the breast and minimize systemic levels. However, the clinical application of this approach for breast cancer treatment...
6.
Islam M, Reineke J, Kaushik R, Woyengo T, Baride A, AlQahtani M, et al.
ACS Appl Mater Interfaces
. 2019 Apr;
11(20):18062-18073.
PMID: 31033278
The goal of this study was to develop bioadhesive food protein nanoparticles using zein (Z), a hydrophobic corn protein, as the core and whey protein (WP) as the shell for...
7.
Durymanov M, Permyakova A, Sene S, Guo A, Kroll C, Gimenez-Marques M, et al.
Mol Pharm
. 2019 Apr;
16(6):2315-2325.
PMID: 31012592
Rapid intracellular degradation of current drug-delivery nanocarriers presents a challenge for achieving ideal controlled drug-release kinetics. Recent in vivo studies have shown that porous hybrid metal-organic frameworks (MOFs), belonging to...
8.
Guo A, Durymanov M, Permyakova A, Sene S, Serre C, Reineke J
Pharm Res
. 2019 Feb;
36(4):53.
PMID: 30790066
Purpose: Intramacrophagic bacteria pose a great challenge for the treatment of infectious diseases despite many macrophage targeted drug delivery approaches explored. The use of biomimetic approaches for treating infectious diseases...
9.
Meythaler J, Fath J, Fuerst D, Zokary H, Freese K, Martin H, et al.
Brain Inj
. 2019 Feb;
33(5):679-689.
PMID: 30744442
Background: Minocycline is a pleomorphic neuroprotective agent well studied in animal models of traumatic brain injury (TBI) and brain ischemia. Methods: To test the hypothesis that administration of minocycline in...
10.
Durymanov M, Kroll C, Permyakova A, Reineke J
Mol Pharm
. 2019 Feb;
16(3):1074-1082.
PMID: 30707590
Robust deposition of extracellular matrix is a significant barrier for delivery of nanotherapeutics and small-molecule anticancer drugs to different tumors including pancreatic ductal adenocarcinoma. Here, we investigated permeation and total...